Aptose Biosciences Inc. (APTOF)
OTCMKTS
· Delayed Price · Currency is USD
2.650
-0.350 (-11.67%)
Apr 7, 2025, 9:30 AM EDT
Aptose Biosciences Employees
As of December 31, 2023, Aptose Biosciences had 36 total employees, including 35 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
36
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,956,154
Market Cap
6.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Music Licensing | 1 |
Federal National Mortgage Association | 8,200 |
Federal Home Loan Mortgage | 8,103 |
Central Bancompany | 2,800 |
Jingbo Technology | 138 |
Endo Inc. | 3,116 |
Aptose Biosciences News
- 11 days ago - Aptose Reports Year End 2024 Results and Corporate Highlights - GlobeNewsWire
- 22 days ago - Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - GlobeNewsWire
- 6 weeks ago - Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
- 6 weeks ago - Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort - GlobeNewsWire
- 7 weeks ago - Aptose Announces Reverse Share Split - GlobeNewsWire
- 7 weeks ago - Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility - GlobeNewsWire
- 7 weeks ago - Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial - GlobeNewsWire
- 3 months ago - Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial - GlobeNewsWire